Retaining patients in buprenorphine treatment is essential in maximising treatment outcomes and minimising mortality risk. Delivery of treatment via novel depot buprenorphine products has the potential to enhance patient adherence and retention in treatment.
With NSW having the largest GLBT community in Australia, it is important that responses to the problems faced by these populations (including a higher risk of drug use and mental health problems) are informed by research evidence.
Changes to the status of cannabis, ranging from legalisation through to tougher enforcement of prohibition are frequently posed. To date, the debate has centred on arguments associated with liberty and harm, but not on economic analyses.
The Northern Territory prison population comprises 92% Indigenous Australians and 88% smokers. The NT prison-smoking ban creates a population-wide abstinence. We aim to extend this period of abstinence into the community.
This project will estimate the social and economic costs related to tobacco use in NSW for 2014. Mortality and morbidity costs attributable to smoking will be estimated as will lost productivity, costs due to fires and the intangible costs due to mortality attributable to smoking.
This project will conduct the first-ever outpatient RCT to test the efficacy, safety and cost-effectiveness of the pharmaceutical cannabinoid nabiximols (Sativex®) for treating cannabis dependence.
The overarching objective of this project is to produce as comprehensive as possible an estimate of the costs of methamphetamine use to Australian society. The intention is also to develop an approach that could be applied in a consistent manner to other drugs in the future.
This innovative, integrated care project was implemented in the South Eastern Sydney Local Health District to improve integration of services provided to those who are frequent attenders to the Emergency Department and have drug and alcohol use disorders.